{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jensen JT"],"funding":["Oregon National Primate Research Center","NCRR NIH HHS","National Institutes of Health","Society of Family Planning","NIH HHS"],"pagination":["110130"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10528587"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["126"],"pubmed_abstract":["We developed and validated the use of ultra-high-performance liquid chromatography-heated electrospray ionization-tandem triple quadrupole mass spectrometry to simultaneously analyze serum concentrations of ethinylestradiol, dienogest, norelgestromin, norethindrone, gestodene, levonorgestrel, etonogestrel, segesterone acetate, medroxyprogesterone acetate, and drospirenone. The calibration range for all targets was 0.009-10 ng/mL, with lower limit of quantification of 0.009 ng/mL for all analytes except gestodene (0.019 ng/mL). We used our assay to check compliance among participants in a clinical trial, confirmed the use of drospirenone in 11 of 13 study participants, and evidence of noncompliant progestins in 2 (levonorgestrel = 1, norethindrone = 1). We conclude that this approach provid"],"journal":["Contraception"],"pubmed_title":["Development and validation of an expanded panel of progestins using liquid chromatography-tandem triple quadrupole mass spectrometry to monitor protocol compliance in hormonal contraceptive pharmacokinetic/pharmacodynamic studies."],"pmcid":["PMC10528587"],"funding_grant_id":["SFPRF12-ES22","P51 OD011092","P51 RR000163"],"pubmed_authors":["McCrimmon S","Blue S","Waites BT","Erikson DW","Jensen JT","Boniface ER"],"additional_accession":[]},"is_claimable":false,"name":"Development and validation of an expanded panel of progestins using liquid chromatography-tandem triple quadrupole mass spectrometry to monitor protocol compliance in hormonal contraceptive pharmacokinetic/pharmacodynamic studies.","description":"We developed and validated the use of ultra-high-performance liquid chromatography-heated electrospray ionization-tandem triple quadrupole mass spectrometry to simultaneously analyze serum concentrations of ethinylestradiol, dienogest, norelgestromin, norethindrone, gestodene, levonorgestrel, etonogestrel, segesterone acetate, medroxyprogesterone acetate, and drospirenone. The calibration range for all targets was 0.009-10 ng/mL, with lower limit of quantification of 0.009 ng/mL for all analytes except gestodene (0.019 ng/mL). We used our assay to check compliance among participants in a clinical trial, confirmed the use of drospirenone in 11 of 13 study participants, and evidence of noncompliant progestins in 2 (levonorgestrel = 1, norethindrone = 1). We conclude that this approach provid","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-06-02T09:24:49.036Z","creation":"2025-04-04T12:54:05.964Z"},"accession":"S-EPMC10528587","cross_references":{"pubmed":["37499736"],"doi":["10.1016/j.contraception.2023.110130"]}}